GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Paliperidone palmitate - ERZOFRI

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

ERZOFRI / Paliperidone ERZOFRI

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
ERZOFRI: product-specific initiation is not the SUSTENNA schedule

The retrieved RX and exact DailyMed renal passages agree on ERZOFRI initiation and monthly maintenance. A mirror plus its underlying label is one label family, not independent corroboration.

Before applying: Keep ERZOFRI initiation, maintenance, switching and missed-dose instructions together; do not add a Day-8 injection from a different paliperidone product.

Also check: ERZOFRI: product-specific initiation is not the SUSTENNA schedule

Official source

Paliperidone palmitate - ERZOFRI

Product / population
Adult ERZOFRI injection; product-specific renal initiation and maintenance only.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.

Exact DailyMed Set ID discovered through its official results page, not a guessed label URL. RX mirror and official label are not independent validation votes.

Renal dosing, restrictions and evidence limits

At Cockcroft-Gault CrCl 50 to <80 mL/min, give 234 mg on Day 1 in the deltoid, then 78 mg monthly in the deltoid or gluteal muscle. Maintenance may be adjusted to 39, 78, 117 or 156 mg; the renal maximum is 156 mg monthly. Use is not recommended below CrCl 50. This is not the SUSTENNA two-injection initiation schedule; no Day-8 ERZOFRI dose is added by this application. Switching and missed-dose instructions require their own full product protocol.

Source revision: Prescribing information revised 03/2025. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492bf9dd-868e-421a-92db-8cca8973aac1

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Paliperidone palmitate - ERZOFRI

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult ERZOFRI injection; product-specific renal initiation and maintenance only.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ERZOFRI

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult ERZOFRI intramuscular extended-release suspension; not another paliperidone formulation.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

ERZOFRI: product-specific initiation is not the SUSTENNA schedule

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation scope

ERZOFRI: product-specific initiation is not the SUSTENNA schedule

The retrieved RX and exact DailyMed renal passages agree on ERZOFRI initiation and monthly maintenance. A mirror plus its underlying label is one label family, not independent corroboration.

How to use this: Keep ERZOFRI initiation, maintenance, switching and missed-dose instructions together; do not add a Day-8 injection from a different paliperidone product.

GlobalRPh RX List - ERZOFRIPaliperidone palmitate - ERZOFRIPaliperidone palmitate - INVEGA SUSTENNA monthly injectionPaliperidone palmitate - INVEGA TRINZA three-month injectionPaliperidone palmitate - INVEGA HAFYERA six-month injectionPaliperidone

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePaliperidone palmitate - ERZOFRIGlobalRPh RX List - ERZOFRI
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/erzofri-drug/

Exact product and population

Adult ERZOFRI intramuscular extended-release suspension; not another paliperidone formulation.

RDM45-SCOPE-paliperidone-erzofri · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Paliperidone palmitate - ERZOFRI

Open original reference

Open / share this exact local source

DailyMed / Shandong Luye Pharmaceutical Co., Ltd. · Adult ERZOFRI injection; product-specific renal initiation and maintenance only.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date: Prescribing information revised 03/2025.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At Cockcroft-Gault CrCl 50 to <80 mL/min, give 234 mg on Day 1 in the deltoid, then 78 mg monthly in the deltoid or gluteal muscle. Maintenance may be adjusted to 39, 78, 117 or 156 mg; the renal maximum is 156 mg monthly. Use is not recommended below CrCl 50. This is not the SUSTENNA two-injection initiation schedule; no Day-8 ERZOFRI dose is added by this application. Switching and missed-dose instructions require their own full product protocol.

RDM45-official-paliperidone-erzofri-202ef58819-C1 · Source locator: Sections 2.4 and 8.6; lines 423-426 and 1010-1012. PI revision 03/2025 at line 250.

Source-specific limits

Exact DailyMed Set ID discovered through its official results page, not a guessed label URL. RX mirror and official label are not independent validation votes.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492bf9dd-868e-421a-92db-8cca8973aac1
Retrieved
2026-09-08
Exact label title
Paliperidone palmitate - ERZOFRI
DailyMed Set ID
492bf9dd-868e-421a-92db-8cca8973aac1
Labeler
Shandong Luye Pharmaceutical Co., Ltd.
Label revision
Prescribing information revised 03/2025.
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date/version
Prescribing information revised 03/2025.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
67c62d8b644afc78c2bb971a682178ffde5db76045b2b551e2fe22419d544704
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ERZOFRI

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult ERZOFRI intramuscular extended-release suspension; not another paliperidone formulation.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At Cockcroft-Gault CrCl 50 to <80 mL/min, give 234 mg on Day 1 in the deltoid, then 78 mg monthly in the deltoid or gluteal muscle. Maintenance may be adjusted to 39, 78, 117 or 156 mg; the renal maximum is 156 mg monthly. Use is not recommended below CrCl 50. This is not the SUSTENNA two-injection initiation schedule; no Day-8 ERZOFRI dose is added by this application. Switching and missed-dose instructions require their own full product protocol.

RDM45-rxlist-paliperidone-erzofri-79788987f5-C1 · Source locator: Dosage Recommendations for Renal Impairment, lines 79-82.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/erzofri-drug/
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
67c62d8b644afc78c2bb971a682178ffde5db76045b2b551e2fe22419d544704

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/erzofri-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
39afbf4519b7922d7e6baf711ac5c76cd71a4561386c2b8646ef1d15bee52e19
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report